United Therapeutics (NASDAQ:UTHR) EVP Paul Mahon Sells 8,300 Shares

United Therapeutics Corporation (NASDAQ:UTHR) EVP Paul Mahon sold 8,300 shares of the firm’s stock in a transaction on Thursday, April 16th. The shares were sold at an average price of $576.82, for a total value of $4,787,606.00. Following the sale, the executive vice president directly owned 45,172 shares of the company’s stock, valued at $26,056,113.04. This represents a 15.52% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

United Therapeutics Price Performance

Shares of United Therapeutics stock opened at $580.51 on Friday. The business has a fifty day simple moving average of $524.67 and a two-hundred day simple moving average of $488.35. United Therapeutics Corporation has a 1 year low of $272.12 and a 1 year high of $607.89. The company has a market capitalization of $25.44 billion, a price-to-earnings ratio of 20.81, a P/E/G ratio of 1.65 and a beta of 0.75.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.78 by $0.92. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.The business had revenue of $790.20 million during the quarter, compared to the consensus estimate of $814.80 million. During the same quarter last year, the firm posted $6.19 EPS. The company’s quarterly revenue was up 7.4% on a year-over-year basis. As a group, equities analysts anticipate that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

UTHR has been the subject of several research reports. Jefferies Financial Group reaffirmed a “buy” rating on shares of United Therapeutics in a report on Monday, March 2nd. HC Wainwright increased their price objective on United Therapeutics from $600.00 to $660.00 and gave the stock a “buy” rating in a research report on Tuesday, March 31st. Oppenheimer increased their price objective on United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a research report on Thursday, February 26th. Raymond James Financial initiated coverage on United Therapeutics in a research report on Friday, April 10th. They set an “outperform” rating and a $700.00 price objective on the stock. Finally, UBS Group increased their price objective on United Therapeutics from $655.00 to $705.00 and gave the stock a “buy” rating in a research report on Thursday, March 5th. Ten analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $601.50.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the company. Clearstead Advisors LLC increased its position in United Therapeutics by 8.9% during the 3rd quarter. Clearstead Advisors LLC now owns 280 shares of the biotechnology company’s stock worth $117,000 after buying an additional 23 shares during the period. Independent Advisor Alliance increased its position in United Therapeutics by 3.3% during the 4th quarter. Independent Advisor Alliance now owns 833 shares of the biotechnology company’s stock worth $406,000 after buying an additional 27 shares during the period. Bessemer Group Inc. increased its position in United Therapeutics by 2.6% during the 3rd quarter. Bessemer Group Inc. now owns 1,126 shares of the biotechnology company’s stock worth $472,000 after buying an additional 28 shares during the period. Florida Financial Advisors LLC grew its holdings in shares of United Therapeutics by 5.4% during the 4th quarter. Florida Financial Advisors LLC now owns 550 shares of the biotechnology company’s stock worth $268,000 after purchasing an additional 28 shares in the last quarter. Finally, NDVR Inc. grew its holdings in shares of United Therapeutics by 5.1% during the 4th quarter. NDVR Inc. now owns 616 shares of the biotechnology company’s stock worth $300,000 after purchasing an additional 30 shares in the last quarter. Institutional investors own 94.08% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.